2021
-
SAN FRANCISCO, Calif., July 22, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it has entered into the clinical trial collaboration and supply agreement with Merck (known as “MSD” outside the United States and Canada), the leader among top immuno-oncology (IO) drugs on the market.
-
2021.07.07 | Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
SAN FRANCISCO, Calif. and SUZHOU, China, July 7, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to US$20 million of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company’s insider trading policy.
-
2021.06.16 | Adagene Announces Inclusion in FTSE Russell Indexes
SAN FRANCISCO, Calif. and SUZHOU, China, June 8, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that it will be added to the FTSE Global Equity Index Series (“GEIS”), including the FTSE Global Total Cap Index and FTSE Emerging Total Cap Index, effective June 21, 2021.
-
2021.05.26 | Adagene to Present at Upcoming Investor Conferences
SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference to be held June 1-4, 2021 and the Goldman Sachs 42nd Annual Global Healthcare Conference to be held June 8-11, 2021.
-
SAN FRANCISCO, Calif. and SUZHOU, China, May 19, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced clinical data from its ADG106 NEObodyTM program. Results from Phase I, open-label, dose-escalation, single center (NCT03802955) and multicenter (NCT03707093) studies of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma were presented in an abstract at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
-
SAN FRANCISCO, Calif. and SUZHOU, China, April 13, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced updated preclinical data from its lead SAFEbodyTM program, ADG126, are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2021.
-
2021.03.31 | Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
SAN FRANCISCO and SUZHOU, China, March 31, 2021 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today reported financial results for the full-year ended December 31, 2020 and provided corporate updates.
-
2021.03.29 | Adagene Announces Clinical Advancement for ADG116
SAN FRANCISCO, Calif. and SUZHOU, China, March 29, 2021 – Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the interim dose-escalation data up to 0.3 mg/kg in its ongoing Phase 1 clinical trial in Australia evaluating the safety and tolerability of ADG116 in patients with advanced/metastatic solid tumors.
-
2021.03.16 | Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
SAN FRANCISCO, Calif. and SUZHOU, China, March 16, 2021 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced the first patients have been dosed in its global Phase 1 clinical trial of ADG126 for the treatment of various advanced solid tumors.
-
2021.02.11 | Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment Option
SAN FRANCISCO, Calif., February 11, 2021 — Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, today announced the closing of its initial public offering (the “IPO”) of 8,457,100 American depositary shares (“ADSs”), at public offering price of US$19.00 per ADS.
-
2021.02.09 | Adagene Inc. Announces Pricing of Initial Public Offering
SAN FRANCISCO, Calif., February 9, 2021 — Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, today announced that it has priced its initial public offering (the “IPO”) of 7,354,000 American depositary shares (“ADSs”), at US$19.00 per ADS. The aggregate offering size of the IPO is approximately US$140.0 million, assuming the underwriters do not exercise their over-allotment option to purchase any additional ADSs.
-
Exelixis will utilize Adagene’s proprietary SAFEbody™ technology to develop novel masked antibody-drug conjugates (ADCs) with potential for improved therapeutic index
-
Collaboration with Richard Childs, M.D., yields potentially first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma
2020
-
2020.12.02 | Adagene Announces Expansion of Leadership Team to Support Strategic Growth
Adagene today announced the expansion of its leadership team. The Company also recently secured laboratory and office space in San Diego to establish a center of excellence for precision medicine and to support its growth in the United States.
-
2020.06.10 | Adagene Announces Strategic Collaboration Agreement with Tanabe Research Laboratories
Tanabe Research Labs and Adagene to develop a first-in-class therapeutic with a next-generation masked antibody drug conjugate (ADC), incorporating Adagene’s SAFEbody™ technology platform
-
Adagene, Inc. a platform-driven, clinical-stage company, today announced that positive results of its novel anti-CD137 agonist, ADG106, from the Phase I trial in China will be presented in a poster at the 2020 American Society of Clinical Oncology (ASCO) Annual meeting.
-
2020.01.09 | Adagene to Present at the 38th Annual J.P. Morgan Healthcare Conference
Adagene, Inc., a clinical-stage, leading-edge oncology immunotherapy company driven by a powerful antibody discovery and engineering platform, today announced that Peter Luo, Ph.D., Co-founder and Chief Executive Officer, will present an overview of the company at the 38th Annual J.P. Morgan Healthcare Conference.
-
2020.01.08 | Adagene Completes $69 Million Series D Financing Led by Growth Investor General Atlantic
Adagene, Inc., a clinical-stage, leading-edge oncology immunotherapy company driven by a powerful antibody discovery and engineering platform, today announced the completion of a $69 million Series D financing, including $50 million from lead investor General Atlantic.
2019
-
2019.10.26 | Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences
Adagene Inc., a clinical stage biotech company with innovative antibody discovery and engineering technologies, announced that it is presenting its lead program at international conferences.
-
2019.04.24 | Adagene and ADC Therapeutics Announce SAFEbody™ License Agreement
Adagene Inc., an antibody engineering and discovery company , and ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that they have entered into a discovery collaboration and license agreement.
-
2019.03.04 | Adagene Announces a Platform Evaluation of the Dynamic Precision Library with Celgene Corporation
Adagene, Inc., an innovative antibody discovery and engineering company, today announced a multi-target platform evaluation with Celgene Corporation. Under the terms of the agreement, Adagene will use its Dynamic Precision Library, to discover antibodies against targets chosen by Celgene.
-
Adagene, Inc., an innovative antibody discovery and engineering company, today announced a collaboration with Dr. Richard Childs, Chief of the Laboratory of Transplantation Immunotherapy at the National, Heart, Lung, and Blood Institute, part of the National Institutes of Health, to discover antibodies targeting a novel antigen expressed on the surface of tumor cells.
2018
-
2018.10.31 | Adagene Announces First Patient Dosed in United States and Acceptance of IND in China for ADG-106
Adagene, Inc., an innovative antibody engineering and discovery company, today announced the dosing of its first patient in its Phase I trial in American for its lead product ADG-106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137.
-
2018.07.09 | US FDA Approves Adagene IO Agonist IND for Solid Tumor and Non-Hodgkin Lymphoma Ph1 Trial
Adagene, Inc., an innovative antibody engineering and discovery company, has received notification from the FDA to proceed on its Investigational New Drug (IND) application to study its lead product (ADG-106) in patients with advanced solid tumors and non-Hodgkin lymphoma.
-
2018.03.26 | Adagene Raises $50 Million in Series C Funding
Adagene Inc., a leading antibody discovery and development company, today announced a $50 million Series C financing, led by Sequoia China, and backed by New World TMT, AVIC Trust, King Star Capital, Gopher Asset Management as well as other investors.
-
2018.03.09 | Adagene and WuXi Biologics Announce Strategic Development and Manufacturing Partnership
Adagene Inc., an emerging biotech company discovering and developing innovative antibody therapeutics for the global market, and WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced a strategic collaboration agreement.